

Marck Biosciences forays into Singapore, Malaysia

BS REPORTER
Ahmedabad, 16 April

Marck Biosciences, manufacturer and marketer of sterile dosages pharma products and blow-fill-seal specialist, is planning to enter the Singapore and Malaysian market. The manufacturing of the company has received an approval from the National Pharmaceutical Control Bureau (NPCB), ministry of health, Malaysia for large volume parenterals, small volume parenterals and ophthalmics. Marck is the only company in India to have received the NPCB approval for its small volume parenterals facility.

Marck, which has presence in about 70 countries across the world, plans to

Marck is the only company in India to have received the NPCB approval for its small volume parenterals facility

introduce a range of small volume parenterals including ophthalmics, irrigation solutions, injectibles and respiratory solutions, and IV parenterals formulations in the large volume parenterals in Singapore and Malaysia.

Bhavesh Patel, managing director, Marck Biosciences, said, "First, our early entry into Malaysia and Singapore opens up a large export market for our products. Second,

the manufacturers of these countries can now get their brands outsourced from Marck. Third, since NPCB is a participant of the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S) - which has 36 participating authorities including those from UK and Australia, the approval will help our registrations endeavor in other PIC/S member countries."

"A strong marketing, sales and distribution team will be put in force by our South East Asia head to accelerate the penetration planned," Patel added.

According to the company, the South-East Asian countries represent a total market of 588 million people and a combined GDP of \$2.2 billion.